구본권 교수
Bon-Kwon Koo
서울대학교 내과 · 의학
연구실 소개
구본권 교수의 연구실은 관상동맥질환의 병태생리학적 기전과 치료 전략을 비침습적 및 침습적 영상 기반으로 규명하는 데 초점을 맞추고 있습니다. 특히 혈관 내 초음파, CT 혈관조영술, 혈류우세도(FFR) 등 다양한 영상 및 기능적 검사 기법을 융합해 관류성 병변과 난이도 높은 분지부 병변의 진단 및 치료 전략 수립에 기여하고 있습니다. 장기적인 심혈관계 예후를 고려한 항판상체 치료 전략의 최적화 및 병변의 취약성 평가 기법 개발에도 주력하고 있습니다.
연구 현황
연구 성과 추이
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
주요 논문
15In conclusion, FFR-guided SB intervention strategy resulted in good functional outcomes.
BACKGROUND: We sought to investigate the mechanism of geometric changes after main branch (MB) stent implantation and to identify the predictors of functionally significant "jailed" side branch (SB) lesions. METHODS AND RESULTS: Seventy-seven patients with bifurcation lesions were prospectively enrolled from 8 centers. MB intravascular ultrasound was performed before and after MB stent implantation, and fractional flow reserve was measured in the jailed SB. The vessel volume index of both the pr
Background: Long-term outcomes of antiplatelet monotherapy in patients who receive percutaneous coronary intervention are unknown. The HOST-EXAM (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis–Extended Antiplatelet Monotherapy) Extended study reports the posttrial follow-up results of the original HOST-EXAM trial. Methods: From March 2014 through May 2018, 5438 patients who maintained dual antiplatelet therapy without clinical events for 12±6 months after percutaneous cor
AIMS: Identification of invasive and radionuclide imaging markers of coronary plaque vulnerability by a single, widely available non-invasive technique may provide the opportunity to identify vulnerable plaques and vulnerable patients in broad populations. Our aim was to assess whether radiomic analysis outperforms conventional assessment of coronary computed tomography angiography (CTA) images to identify invasive and radionuclide imaging markers of plaque vulnerability. METHODS AND RESULTS: We
In patients with intermediate stenosis who were being evaluated for PCI, FFR guidance was noninferior to IVUS guidance with respect to the composite primary outcome of death, myocardial infarction, or revascularization at 24 months. (Funded by Boston Scientific; FLAVOUR ClinicalTrials.gov number, NCT02673424.).
대표 연구 분야
구본권 교수의 연구를 Nubint에서 더 깊이 살펴보세요
이 연구실의 논문을 앱에서 열어 AI와 함께 읽고, 핵심을 요약하고, 내 글에 인용하세요.